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The differentiation of bone marrow-derived lymphocytes in mice is characterized 
by the sequential appearance of different surface markers. IgM is the first isotype to 
appear, and IgM  ÷ cells subsequently acquire IgD. The acquisition of IgD appears to 
be antigen and T  cell independem  (1). The roles of these two surface isotypes in the 
triggering of B ceils is the subject of intensive study. When mature B cells  bearing 
both isotypes are triggered by mitogens, IgD is  lost and  the cells differentiate  into 
IgM secreting plasma cells (1-3). 
Recent evidence indicates that several nonsecreting B cell tumors from humans (4, 
5) and mice (6) have the capacity to secrete IgM under the influence of mitogens (5), 
T  cells  (4), or after fusion to myeloma cells  (7). One of the murine tumors, BCLx, has 
been used in the present studies  to investigate the pathway of B cell differentiation 
that is characterized by the acquisition of IgD. The uncultured tumor cells bear large 
quantities of surface IgM and trace amounts of IgD (8-10). Thus, both the phenotypic 
characteristics  (8)  and,  in  addition,  the  functional  properties  (9,  10)  of BCLx cells 
suggest that they are analogous to immature B cells.  In the present studies we have 
demonstrated that cultivation of BCL1 ceils  results in markedly increased expression 
of surface IgD in the absence of IgM secretion. 
Materials and Methods 
Mice.  BALB/c mice were obtained  from  Cumberland View  Farms,  Clinton,  Tenn.  The 
BCL1 tumor was maintained in vivo by intravenous  passage of 10  e spleen cells obtained from 
a tumor-bearing mouse. 
Culture Conditions.  Peripheral  blood  and  spleen  cells were  obtained  from  mice  that  had 
carried  the tumor for 8-12 wk and were prepared and cultured as previously described  (11)  1 
without  the addition of either  2-mercaptoethanol  or lipopolysaccharide  (LPS). Greater than 
90% of the cell populations  employed are tumor cells as judged by morphology and expression 
of idiotype  (9,  12). Cells were  incubated  in  250-ml culture  flasks (Falcon  Labware,  Div. of 
Becton, Dickinson & Co., Oxnard, Calif.) at 2 ×  106/ml (30-50 ml/flask),  in RPMI-1640 with 
10% fetal calf serum  (FCS) (Grand  Island  Biological Co., Grand Island,  N. Y.). Under these 
conditions, BCLx cells do not secrete IgM. x 
Immunofluorescence.  Indirect  immunofluorescence analysis of tumor cells on the fluorescence- 
activated  cell sorter (FACS III, Becton, Dickinson & Co., Rutherford, N. J.) was performed  as 
* Supported by National Institutes of Health grants AI-11851,  AI-10967,  AI-12789,  and CA-23115, and 
by Uniformed Services University of the Health Sciences grants" R08307 and R08308. 
1  Isakson, P. C., K. A. Krolick,  J. W. Uhr, and E. S. Vitetta. Manuscript submitted for publication. 
J. ExP. MEn. (~)The Rockefeller University Press • 0022-1007/80/03/0749/06 $1.00  749 
Volume 151  March  1980  749-754 750  ISAKSON ET AL.  BRIEF DEFINITIVE REPORT 
500 
400 
300 
-  CULTURE  [ 
--  Anti-8 
.... Control 
,,,c: 200  L 
m  100 
D  ,  ,  ,  ,  T  ,  ,  ,  I  ,  ,  Z  ', 
J 500 
-  [u  1 
'"  +  C  LTURE 
o  400 
300 
200 
100 
FLUORESCENCE  INTENSITY 
FIG.  1.  Immunofluorescence analysis of BCL1 cells stained with anti-& Blood cells from tumor- 
bearing animals were cultured at 2 ×  106/ml for 4 d and, along with uncultured blood cells, were 
stained with hybridoma anti-8 or the control mouse IgG2A (RPC-5) and F1-RAM'y F(ab%. Cells 
were analyzed on the FACS, and the results were plotted as cell number vs. fluorescence intensity. 
previously described  (9)  with  either  a  hybridoma  anti-8  (H  10.4.22)  or  a  control  IgG2A 
myeloma protein (RPC-5)  (Litton Bionetics, Kensington, Md.), followed by incubation with 
fluorescein-conjugated F(ab% rabbit anti-mouse--f. 
Cell Surface Iodination.  Surface  molecules were  labeled with  12SI-Na by  lactoperoxidase- 
catalyzed iodination, and  the  immunoglobulins were  precipitated from  the cell lysate and 
analyzed as previously described (12). 
Radioimmunoassay for Surface Ig.  The  antibodies used  for  this assay were  affinity-purified 
rabbit anti-mouse-# and goat anti-mouse-& Preparation and  iodination of the rabbit anti-# 
and control Ig is detailed elsewhere. ~ Affinity-purified goat anti-mouse-8 was prepared in goats 
by repeated injections of 500 #g of TEPC-1017  (an IgD, myeloma protein [F. Finkelman, S. 
Kessler, F. Mushinski, and M. Potter. Manuscript in preparation.]) in adjuvant. After adsorp- 
tion with an IgM, myeloma (TEPC-183)  and BALB/c serum, the serum was affinity purified 
on TEPC-1033 Sepharose (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. 
J,) (IgD,) (F. Finkelman, S. Kessler, F. Mushinski, and M. Potter. Manuscript in preparation.). 
•  •  o  •  125  1  Tumor cells or normal spleen cells were incubated for 30 mm at 4  C with 200 #1 of  I-labe ed 
antibody in 5% FCS-phosphate-buffered saline (PBS)  (with  10 mM azide) followed by three 
washes with PBS-azide. Cells were transferred to a fresh tube and counted directly in a gamma 
counter.  For each  point,  four concentrations of ~2SI-antibody  were  tested,  and  the  average 
counts per minute bound per 105 cpm input was calculated. Under these conditions, binding 
of ~25I-anti-# and ~25I-anti-8 to BALB/c spleen cells was linear with respect to concentration of 
antibody and number of cells assayed. Binding of radioiodinated normal Ig to normal or tumor 
cells was always <200 cpm/10  s input cpm. 
Results 
Immunofluorescence  Analysis.  Prior studies of BCLx tumor cells with  both  immuno- 
fluorescence  and  biochemical  techniques  demonstrated  that  these  cells  bear  large 
quantities of surface IgM but only trace amounts of IgD  (8-10).  Thus,  Fig.  1 shows 
that  freshly prepared BCL1  cells stained minimally with  anti-& In contrast,  86%  of 
BCL~ cells cultured for 4 d  without added mitogens stained brightly with hybridoma 
anti-6 but  not  with  a  control myeloma protein of the same subclass  (RPC-5).  The ISAKSON  ET  AL.  BRIEF  DEFINITIVE  REPORT  751 
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FIG.  2.  Immunopreeipitation of lysates of cells radioiodinated before and after culture. BCL~ cells, 
cultured for 6 d  at 2 ×  10°/ml, were washed and iodinated; fresh BCLI blood cells were iodinated 
at the same time. The lysates were precipitated with RAMIg or control  rabbit  antisera (anti-~  X 
174) and Staphylococcus aureus. Complexes were eluted and electrophoresed under reducing conditions 
on 7.5% SDS gels. 
cultured  cells  that  stained  with  anti-8  were  very  heterogeneous  with  respect  to 
fluorescence intensity, which suggests a variable density of surface IgD. This finding 
indicates that the vast majority of BCLI tumor cells differentiate in vitro and acquire 
the surface immunoglobulin phenotype of a more mature B cell. 
Biochemical Analysis  of Surface Ig.  To obtain  biochemical evidence that  cultured 
BCL1 cells acquire IgD, cells were iodinated, either before or after culture, and the 
lysates were analyzed by immunoprecipitation and sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (SDS-PAGE). Immunoprecipitation with rabbit anti-mouse 
Ig (RAMIg)  of lysates from uncultured cells demonstrated substantial  quantities of 
#-chain but little or no &chain (Fig. 2).  Lysates from radioiodinated cultured cells, 
however, contained readily detectable IgD as determined by the presence of radio- 
active &chain on SDS-PAGE.  Estimation of the areas under the #- and 8-peaks in 
several experiments showed at  least a  three- to fourfold decrease in the #:&ratio of 
cultured cells. Analogous results with regard to &chain were obtained with affinity- 
purified goat anti-8 (data not shown). 
Radioimmunoassay for Surface Ig.  To further quantify the relative amounts of IgM 
and  IgD  on  cultured  BCL1  cells,  cells  were  treated  with  radioiodinated,  affinity- 
purified antibodies directed against ~- or &chains. As shown in Table I, BCLz cells 
bound  substantially  more  x25I-anti-/~ than  normal  spleen  cells  (assuming  40%  of 
normal spleen cells and  100% of BCL1 cells are IgM positive) (9).  In the experiment 
shown,  binding  of z25I-anti-#  was  unchanged  on  cells  cultured  for  6  d;  in  other 
experiments,  increased  binding  of 125I-anti-/~ (up  to  a  twofold increase)  was  often 
observed.  In  contrast,  binding  of  125I-anti-8  to  uncultured  BCL1  cells,  although 752  ISAKSON  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Radioimmunoassay  for Cell Surface IgM and IgD on BCL1 Cells 
Cell source  Days in 
culture* 
Bound to cells 
x25I_anti.p,  ~  t2nI.anti.~ 
~:811 
cp?n 
BALB/c spleen¶  0  598  2,582  0.2 
BCLI spleen**  0  2,764  933  3.0 
BCLI spleen**  6  2,529  3,144  0.8 
BCL1 blood**  0  2,467  855  2.9 
BCL1 blood**  6  2,540  2,603  1.0 
* Cells were cultured at 2 X  lOS/ml. 
:~ 1 X  10  5 cprn input (2 X  10  s cpm/pg). 
§ 2 ×  10  s cpm input (2 X  l0  s cpm/p.g). 
[[ cpm anti-p bound:cpm anti-8 bound. 
1 5 X  10  s cells/tube were assayed. 
** 2 X  10  s cells/tube were assayed. 
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Fro.  3.  Kinetics of appearance of IgD during in vitro culture. BCL1  blood and spleen cells were 
cultured at  2  ×  10e/ml  for  1,  3,  or  5  d.  Binding of l~SI-anti-/t  and  l~SI-anti-8 was performed as 
described in  Materials  and  Methods;  2  X  10  n BCLi  cells or 5  X  10  e  BALB/c  spleen cells  were 
assayed. ~:8-ratios were calculated on the basis of counts bound per 1 X  105 cpm added for anti-#, 
and 2  ×  105 cpm added for anti-8. 
reproducibly higher than the control, was very low compared with binding to normal 
cells. After cell culture there was a  dramatic  increase in 125I-anti-8  binding to BCL1 
cells  (Table  I)  but  no increase  in binding of the control Ig  (data not shown).  The 
increased binding of 125I-anti-8 after culture is reflected in the decreased binding ratio 
of anti-/~:anti-8  ~:6").  The  kinetics  of appearance  of IgD  are  shown  in  Fig.  3  and 
indicate that increased levels of surface IgD could be detected as early as 1 d of culture 
and levels continued to increase until they plateaued at 3-5 d. It should be emphasized 
that because the binding assays were performed  under nonsaturating conditions, the 
#:8-ratios  calculated  here  are  relative  ones  and  do not  reflect  absolute  amounts  of 
surface Ig. 
Discussion 
The  present  studies  indicate  that  culture  of  BCLa  tumor  cells  can  result  in  a 
markedly  increased expression  of cell  surface  IgD.  The  IgD was  measured  by three 
techniques: immunofluorescence using the FACS, immunoprecipitation of radioiodi- 
nated surface immunoglobulin and analysis by SDS-PAGE, and a radioimmunoassay 
with heavy chain-specific  antibodies.  The results of the latter assay suggest  that the ISAKSON ET AL.  BRIEF DEFINITIVE REPORT  753 
density of IgD on uncultured  BCL1 ceils is  ~l/10th  of that  found on normal adult 
spleen cells.  After 3-5 d  of culture,  the density of IgD increased  three- to fourfold. 
Earlier studies have shown a  loss of surface IgD during differentiation of B cells into 
plasma cells  (1-3)  but  to our knowledge,  this  is the first  demonstration  of in  vitro 
acquisition of surface IgD. 
A  significant development in B cell immunology was the demonstration by Fu et 
al.  (4,  5)  and  Kishimoto  (13)  that  neoplastic  human  B  lymphocytes  could  be 
stimulated in vitro to differentiate into Ig-secreting plasma cells. Similar observations 
have  been  made  with  the  BCLx  tumor,  i.e.,  cultivation  of BCL1  cells  with  LPS 
stimulates them to secrete IgM (11)  bearing the same idiotype as the surface Ig of the 
unstimulated cells (12). The present findings extend the concept that tumor cells can 
differentiate.  Thus,  cultivation  of  BCL1  ceils  in  the  absence  of  LPS  results  in 
differentiation along a  different pathway, i.e., acquisition  of an Ig phenotype char- 
acteristic of a more mature B lymphocyte. It is unclear whether this is a spontaneous 
maturation event related to removal of host suppressive influences or caused by trace 
amounts of stimulatory factors (growth factors or mitogens) in the FCS.  Regardless, 
the  BCL1  cells  may provide  a  useful  model  for analysis  of the  events  involved  in 
expression of IgD and the factors that determine which pathway of differentiation is 
chosen by B cells. 
Summary 
Murine BCLa tumor cells bear large amounts of surface IgM and trace amounts of 
surface IgD. In the present studies we have shown that cultivation of these cells, in 
the absence of lipopolysaccharide, results in the acquisition of IgD by virtually all the 
cells. These results suggest that BCL1 cells can differentiate in vitro into more mature 
B cells and offer an attractive model for analyzing the factors controlling appearance 
of IgD on a monoclonal cell line. 
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